Brought to you by 
AbbVie licenses Lupin's MALT1 inhibitors for hematological cancers
04 Feb 2019
Executive Summary
AbbVie Inc. licensed exclusive worldwide development and commercialization rights to Lupin Ltd.'s mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor program. Lupin retains commercialization rights in India.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie licenses Lupin's MALT1 inhibitors for hematological cancers
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice